Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia.
Catherine AftandilianLourdes EguigurenRoshni MathewAnna MessnerPublished in: Pediatric blood & cancer (2019)
Mucormycosis in pediatric oncology patients is a rare invasive fungal infection associated with significant morbidity and mortality. We describe five patients diagnosed with mucormycosis during induction chemotherapy for acute lymphoblastic leukemia at our institution. All of the patients in our series survived, some in spite of having disseminated disease. Most of the patients' chemotherapy was modified with the aim of controlling their leukemia while minimizing immunosuppression until their fungal infection was under control. Although mucormycosis is frequently fatal, rapid diagnosis and a multidisciplinary approach can lead to excellent outcomes, even in patients undergoing intensive chemotherapy.
Keyphrases
- end stage renal disease
- acute lymphoblastic leukemia
- ejection fraction
- newly diagnosed
- patients undergoing
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- type diabetes
- palliative care
- radiation therapy
- insulin resistance
- young adults
- adipose tissue
- metabolic syndrome
- quantum dots
- glycemic control